Disculpa, pero esta entrada está disponible sólo en Inglés Estadounidense. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
The proposed guideline will replace ‘points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome CPMP/EWP/785/97’. Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder in which abdominal discomfort or pain is associated with changes in bowel habits, stool consistency and other features of disordered defecation.
| Consultation start date | 08/06/2012 |
|---|---|
| Consultation end date | 31/08/2012 |
| Email address for submissions | gastroenterologydg@ema.europa.eu |